ZBIO (Zenas BioPharma) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 27, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Zenas BioPharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Zenas BioPharma's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Zenas BioPharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Margin of Safety % (DCF Earnings Based) falls into.

Save Embed

;

Save Embed

;

Zenas BioPharma Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.